The well-known, Ozempic (brand name for semaglutide), belongs to a group of drugs known as GLP-1 receptor agonists. GLP-1 receptor agonists are used for type 2 diabetes and weight loss, and mimic the way the naturally occurring hormone, GLP-1, acts in the body. Now, fibromyalgia is making a potential appearance on this management list, according to a Medscape article https://tinyurl.com/nheek3ew.
Reporting on a “large-scale health records analysis”, the article states – “The use of GLP-1 receptor agonists was linked to lower pain and fatigue in patients with fibromyalgia”
‘“The way that I use it in my practice these days is that if I have a patient with chronic pain or with fibromyalgia who has comorbidities that already have an FDA approval for GLP-1 use, such as obesity, diabetes, or obstructive sleep apnea, I would encourage them to go to their primary care physician and maybe consider getting started on a GLP-1,” said presenter Nouran Eshak, MB ChB, of the Mayo Clinic in Scottsdale, Arizona.’
However, the article also lists several limitations to the study including “…Researchers were unable to account for confounders such as duration of illness, symptom severity, GLP-1 dosage, or access to healthcare.”
Disclaimer: This post is not a recommendation, rather just a report. Please discuss with your doctor if you are considering starting any new medication or if you are experiencing side effects or worsening symptoms.
